Eli Lilly (LLY): FY25 Q3 earnings call, Oct 30, 2025

Thu, Oct 30Earnings callSpeaker-labelled transcriptEli Lilly

No Kalshi or Polymarket word markets were listed for Eli Lilly’s Oct 30, 2025 earnings call (FY25 Q3). The transcript is searchable below (quotes of at most 25 words).

Updated

Transcript

quotes of at most 25 words

Speaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.

3 matches for “Vial”; 3 quoted, at least 25 words apart.

Lucas Montarcecompanyprepared

…71% share of new prescriptions. We saw strong uptake of Zepbound in vials, which comprise approximately 30% of total U.S. Zepbound prescriptions and over 45%…

Asad Haideranalystqa

…continuing to see the most rapid growth in the obesity market. Zepbound vials are now almost 40% of new scripts. And related on ex U.S.…

Ilya Yuffacompanyqa

…more offerings, whether you include being able to pick up your Zepbound vial at a local Walmart, which we announced yesterday or expanding the offering…

Agents: this page as TSV at /api/v1/appearances/eli-lilly:2025-10-30:earnings_call · words: /api/v1/brief?appearance=eli-lilly:2025-10-30:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP